| 4.4 0.01 (0.23%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.58 | 1-year : | 9.1 |
| Resists | First : | 6.49 | Second : | 7.79 |
| Pivot price | 5.27  |
|||
| Supports | First : | 4.38 | Second : | 3.64 |
| MAs | MA(5) : | 4.5 |
MA(20) : | 5.75 |
| MA(100) : | 5.16 |
MA(250) : | 4.99 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 1.6 |
D(3) : | 1.6 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 7.79 | Low : | 2.68 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INZY ] has closed above bottom band by 23.6%. Bollinger Bands are 121.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 18 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.63 - 4.66 | 4.66 - 4.69 |
| Low: | 4.33 - 4.36 | 4.36 - 4.4 |
| Close: | 4.34 - 4.4 | 4.4 - 4.45 |
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Tue, 16 Apr 2024
Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update - MarketBeat
Thu, 11 Apr 2024
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Mon, 08 Apr 2024
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 ... - GlobeNewswire
Fri, 05 Apr 2024
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Tue, 02 Apr 2024
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference - Yahoo Finance
Tue, 26 Mar 2024
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency ... - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 92.9 (%) |
| Shares Short | 2,580 (K) |
| Shares Short P.Month | 2,320 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27.9 % |
| Return on Equity (ttm) | -55 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -3.22 |
| PEG Ratio | -0.3 |
| Price to Book value | 1.93 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|